Skyrizi

Skyrizi was selected for Cost Review by the Board on May 20, 2024.

Relevant Information:

• Presentation of findings from the drugs referred to the Stakeholder Council  - PDF - 1.71 MB
• Written comments concerning list of therapeutic alternatives ( - PDF - 4 MB30 days).
• Comments concerning Board selection of prescription drug products for cost review. - PDF - 17.27 MB

The 60 day comment period was posted on May 23, 2024 and comments were accepted until July 22, 2024. 

The request for information for Skyrizi was distributed/posted on May 28, 2025. The Board may collect additional information on the drugs selected for the Cost Review Study Process, as outlined in COMAR 14.01.04.04

Read the archived RFI notice